Outcomes in Patients With Brain Metastasis from Esophageal Carcinoma

Share this content:

the ONA take:

Although the prognosis of patients with esophageal cancer and brain metastases remains poor overall, those with good performance status and a limited number of brain lesions have longer median overall survival, according to a study published in the Journal of Gastrointestinal Oncology.

For the study, investigators analyzed demographic and clinical data from 49 patients with brain metastases from stage 1 to 4 primary esophageal carcinoma. Patients had undergone surgery, radiation, or a combination of treatment modalities between 1998 and 2015 at H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida.

Results showed that median overall survival following cancer diagnosis was 24 months, and median survival after the detection of brain metastases was 5 months.

After adjusting for multiple variables, patients with recursive partitioning analysis (RPA) classification I or II disease had significantly improved survival vs those with class III disease (P <.01). In addition, patients with 3 or more brain metastases had significantly poorer overall survival compared with those with only 1 or 2 brain metastases (P <.01).

The study further revealed that patients with a limited number of CNS lesions who received definitive therapy with surgery or stereotactic radiosurgery had improved outcomes from aggressive management vs those who underwent whole-brain radiotherapy alone.

Gastrointestinal Oncology
Gastrointestinal Oncology

Background: Brain metastases from esophageal carcinoma have historically been rare and associated with poor prognosis. With improvements in systemic disease control, the incidence of brain metastases is expected to rise. To better inform management decisions, we sought to identify factors associated with survival in patients with brain metastasis from esophageal cancer.

Methods: We retrospectively identified 49 patients with brain metastasis from stage I–IV primary esophageal cancer treated with surgery, radiation, or a combination of modalities at our tertiary referral center between 1998 and 2015. Medical records were reviewed to collect demographic and clinical information.

Results: Median age at diagnosis of the primary esophageal cancer was 60 years. Forty-one (84%) patients were male and forty patients (82%) had adenocarcinoma. Median overall survival (MS) following esophageal cancer diagnosis was 24 months (range, 3–71 months), and median survival after the identification of brain metastases was 5 months (range, 1–52 months). On univariate analysis, only patients with poor Karnofsky performance status (KPS <70), recursive partitioning analysis (RPA) classification (III), or 3 or more brain metastases were found to have worsened survival after the diagnosis of brain metastases (all P<0.01). Factors not associated with survival were age, gender, histology (adenocarcinoma vs. other), palliative-intent treatment of the primary tumor, time to diagnosis of brain metastases from initial diagnosis, uncontrolled primary tumor at time of brain metastasis diagnosis, or extracranial metastases. On multivariate analysis (MVA, KPS excluded), patients with RPA class I (MS, 14.6 months) or II (MS, 5.0 months) disease had significantly improved overall survival compared to class III disease (MS, 1.6 months, P<0.01). Also on MVA, patients with 1 (MS, 10.7 months) or 2 (MS, 4.7 months) brain metastases had significantly improved overall survival compared to patients with 3 or more brain metastases (MS, 0.3 months, P<0.01). For the 36 patients with 1–2 brain metastases and KPS ≥70, MS was 11.1 months.

Conclusions: While the prognosis for esophageal cancer metastatic to brain remains poor overall, we found that patients with good performance status and limited number of brain lesions have superior survival. Aggressive management may further improve outcomes in these patients.

Keywords: Brain metastasis; esophageal cancer; recursive partitioning analysis (RPA) score 

Submitted Jan 23, 2016. Accepted for publication Feb 16, 2016.

doi: 10.21037/jgo.2016.03.12  

Page 1 of 5
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs